Women’s health exits reveal what buyers will pay for

In a review of nearly 300 exits, the median sale price was 5.9 times capital raised among companies that disclosed both figures. One in six in that group sold for less than it raised.

Author
HDM Staff
Save
Share

    A founder selling menopause care has at least two customers to understand. One is the woman deciding whether to pay for another visit. The other, years later, may be a company deciding whether to buy the business. A review of nearly 300 women’s health exits suggests how much turns on the distance between those two decisions. Among businesses for which both figures were available, the median sale price was 5.9 times the capital raised, according to Lakeisha Landrum Pierre, co-founder and managing partner of Emmeline Ventures. Roughly one in six sold for less than it had raised.

    Those figures describe companies that reached an exit and disclosed enough financial information to make the calculation. They tell a founder something about what buyers valued, while leaving open what any particular investor took home or what happened to companies that never sold. Landrum Pierre brought the findings to The Real Women’s Health Investment Thesis, a November 17 discussion in Las Vegas led by Sasha Kelemen, who leads women’s health investment banking at Baird. Joining them were Carli Sapir, founding partner of Amboy Street Ventures, and Trish Costello, founder of Portfolia.

    The buyer who comes last

    Landrum Pierre asked the audience to picture a lemonade stand. The owner can sell by the cup, persuade a school to buy for its students or get a town to cover the cost. Each version serves thirsty children. Each also requires the proprietor to prove something different. Healthcare founders readily recognize the patient, employer and insurer in that example. The person who might eventually buy the stand itself tends to enter the conversation much later.

    For Landrum Pierre, “you really design for your last buyer.” Her firm’s public exit ledger grew out of an effort to get past aggregate deal values and look at individual companies. The measure she follows is “value created per dollar raised.” Two companies can sell for the same amount yet have had very different needs for outside money along the way. The distinction matters to a founder deciding what to finance with the next round.

    Direct sales can establish demand quickly. A woman who buys a product again gives the company evidence that its brand or service has continuing value. Landrum Pierre described supplements as a category that tended to sell relatively quickly in the data, often in smaller transactions. Pursuing insurance coverage can consume more time and money. The evidence assembled to win coverage, however, may be precisely what makes a business attractive to a pharmaceutical or medical technology buyer. An employer has another interest altogether. It wants to know what the benefit saves.

    How a successful financing can complicate a sale

    Kelemen has seen buyers walk away from businesses they liked before making a bid. The amount of capital already raised gave the prospective purchaser a sense of the minimum price the board would accept. When that figure looked too far above what the buyer could justify, the discussions ended. For founders weighing a larger round, the consequence can surface years after the financing earns its headlines.

    Sapir described the view from her earlier work in private equity. A prospective buyer could assess a business on its own economics without sharing a venture investor’s need for a particular return. The investor might still occupy a board seat and have a say over whether the deal went ahead. Sapir urged founders to approach acquisition teams early, with the aim of “understanding why they might be interested in your product.” A strategic buyer, a private equity firm and public investors each need their own reason to commit.

    Costello offered a question for the founder negotiating a round. In her words, “how do I create value over time?” It leads to a more useful discussion about the milestones the money will finance and which prospective partners will care about reaching them. She urged founders to cultivate more than one relationship and exercise judgment about the information they share. An early conversation can teach a company about a prospective buyer’s requirements without giving that buyer a privileged position in an eventual sale.

    Gameto gave Costello a case with a clock attached. When Portfolia invested, it expected an exit might take five years. About 18 months later, a proposed acquisition was on the table. Ferring and Gameto’s announcement of the agreement makes the distinction important. The stated potential transaction value includes milestone payments. The investment timeline surprised Costello, but the commercial relationship that made a transaction possible had taken years to build.

    Who is still missing from the market?

    The financing discussion took on a different cast when Kelemen asked whether menopause care had become crowded. Costello could remember pitching the idea to venture colleagues who could barely imagine a product beyond a small fan for hot flashes. Now a woman can choose among several platforms for information or care. From an investor’s desk that can look like a mature market. From the perspective of a woman whose coverage puts those services out of reach, it looks very different.

    Sapir singled out women covered by Medicaid as a population the businesses she had discussed were barely reaching. Landrum Pierre said affluent women had been among the earliest adopters. A startup seeking its next customers among people with less disposable income has to revisit the payment question that opened the panel. An individual might want the service very much and still depend on a health plan or clinic to make it available. Strong sales to early customers answer only part of that question.

    The investors also drew a boundary around what counts as a women’s health investment. Sapir welcomed cardiovascular and other technologies addressing conditions that affect women differently. A general cardiovascular innovation with “no gender lens on that innovation” would be a difficult use of a dedicated fund, she said. Costello described a practical test at Portfolia. She asks whether studies include Black and brown women and whether the team understands how its diagnostic or product performs for them. The answer can determine whether Portfolia invests.

    Several ideas still intrigued the panel, including continuous hormone monitoring for Sapir and earlier diagnosis of endometriosis for Costello and Landrum Pierre. Costello returned to the work that begins after a promising diagnostic has demonstrated what it can detect. “We need to get them paid for,” she said. For the founder, the next milestone might therefore be a coverage decision. For a patient who has spent years looking for an explanation for her symptoms, that same decision determines whether she ever gets to use the test.

    Investors discuss the buyers and payment models behind women’s health exits on the Startup Stage. Photo credit: HLTH USA 2026.